Versor Investments LP Purchases New Shares in Sabra Healthcare REIT, Inc. $SBRA

Versor Investments LP purchased a new stake in Sabra Healthcare REIT, Inc. (NASDAQ:SBRAFree Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 34,800 shares of the real estate investment trust’s stock, valued at approximately $659,000.

Several other institutional investors and hedge funds have also modified their holdings of SBRA. Principal Financial Group Inc. grew its stake in shares of Sabra Healthcare REIT by 21.6% in the fourth quarter. Principal Financial Group Inc. now owns 24,953,351 shares of the real estate investment trust’s stock valued at $472,617,000 after acquiring an additional 4,431,897 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. grew its stake in shares of Sabra Healthcare REIT by 1,019.8% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,005,374 shares of the real estate investment trust’s stock valued at $56,922,000 after acquiring an additional 2,736,993 shares in the last quarter. Balyasny Asset Management L.P. acquired a new position in shares of Sabra Healthcare REIT in the second quarter valued at about $49,955,000. Qube Research & Technologies Ltd grew its stake in shares of Sabra Healthcare REIT by 856.5% in the second quarter. Qube Research & Technologies Ltd now owns 1,398,965 shares of the real estate investment trust’s stock valued at $25,797,000 after acquiring an additional 1,252,708 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its stake in shares of Sabra Healthcare REIT by 33.7% in the third quarter. JPMorgan Chase & Co. now owns 3,589,253 shares of the real estate investment trust’s stock valued at $66,904,000 after acquiring an additional 903,841 shares in the last quarter. 99.40% of the stock is currently owned by institutional investors and hedge funds.

Sabra Healthcare REIT Stock Up 0.6%

SBRA stock opened at $21.10 on Thursday. The stock has a market capitalization of $5.32 billion, a P/E ratio of 33.49, a price-to-earnings-growth ratio of 1.68 and a beta of 0.67. The company has a current ratio of 4.72, a quick ratio of 4.72 and a debt-to-equity ratio of 0.96. Sabra Healthcare REIT, Inc. has a 12 month low of $17.08 and a 12 month high of $21.11. The firm has a 50-day moving average price of $20.26 and a 200-day moving average price of $19.49.

Sabra Healthcare REIT (NASDAQ:SBRAGet Free Report) last posted its earnings results on Wednesday, April 29th. The real estate investment trust reported $0.16 EPS for the quarter, hitting analysts’ consensus estimates of $0.16. The firm had revenue of $221.75 million during the quarter, compared to analysts’ expectations of $209.20 million. Sabra Healthcare REIT had a net margin of 19.22% and a return on equity of 5.60%. The business’s revenue for the quarter was up 20.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.37 earnings per share. Sabra Healthcare REIT has set its FY 2026 guidance at 1.550-1.590 EPS. As a group, equities research analysts anticipate that Sabra Healthcare REIT, Inc. will post 1.5 EPS for the current fiscal year.

Sabra Healthcare REIT Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 29th. Stockholders of record on Friday, May 15th will be issued a $0.30 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $1.20 dividend on an annualized basis and a dividend yield of 5.7%. Sabra Healthcare REIT’s dividend payout ratio is 190.48%.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on SBRA. Cantor Fitzgerald upped their price objective on shares of Sabra Healthcare REIT from $21.00 to $22.00 and gave the stock a “neutral” rating in a research report on Monday. Truist Financial upped their price objective on shares of Sabra Healthcare REIT from $21.00 to $22.00 and gave the stock a “hold” rating in a research report on Friday, March 13th. Wells Fargo & Company increased their target price on shares of Sabra Healthcare REIT from $21.00 to $22.00 and gave the stock an “overweight” rating in a report on Thursday, March 26th. UBS Group increased their target price on shares of Sabra Healthcare REIT from $21.00 to $22.00 and gave the stock a “neutral” rating in a report on Wednesday. Finally, Weiss Ratings cut shares of Sabra Healthcare REIT from a “buy (a-)” rating to a “buy (b+)” rating in a report on Friday, May 1st. Five investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, Sabra Healthcare REIT has a consensus rating of “Moderate Buy” and a consensus target price of $22.20.

Get Our Latest Report on SBRA

About Sabra Healthcare REIT

(Free Report)

Sabra Healthcare REIT, Inc (NASDAQ: SBRA) is a real estate investment trust that acquires, owns and operates net‐lease healthcare properties. Its diversified portfolio spans senior housing communities, skilled nursing and rehabilitation centers, outpatient medical facilities, medical office buildings, hospitals and life science properties. Sabra structures long‐term, triple‐net lease agreements with healthcare operators, providing stable rental income streams while allowing tenants to focus on patient care and operational excellence.

Serving a broad spectrum of care segments, Sabra’s tenants include both regional and national providers of assisted living, independent living, memory care, post‐acute rehabilitation and research and development laboratories.

Featured Stories

Want to see what other hedge funds are holding SBRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sabra Healthcare REIT, Inc. (NASDAQ:SBRAFree Report).

Institutional Ownership by Quarter for Sabra Healthcare REIT (NASDAQ:SBRA)

Receive News & Ratings for Sabra Healthcare REIT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sabra Healthcare REIT and related companies with MarketBeat.com's FREE daily email newsletter.